Section Arrow
Quote
ESPR.NASDAQ
- Esperion Therapeutics
Quotes are at least 15-min delayed:2026/03/28 08:44 EDT
Regular Hours
Last
 2.74
-0.11 (-3.86%)
Day High 
2.84 
Prev. Close
2.85 
1-M High
3.385 
Volume 
2.33M 
Bid
2.74
Ask
2.84
Day Low
2.73 
Open
2.82 
1-M Low
2.385 
Market Cap 
681.33M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.63 
20-SMA 2.75 
50-SMA 3.11 
52-W High 4.175 
52-W Low 0.6925 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.11/0.25
Enterprise Value
931.46M
Balance Sheet
Book Value Per Share
-1.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
403.14M
Operating Revenue Per Share
0.43
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health19.38-1.48-7.09%40.92PE
HLNHaleon plc9.8+0.05+0.51%19.79PE
TEVATeva Pharmaceutical Industries Limited28.74-1.04-3.49%24.64PE
ELANElanco Animal Health23.13-1.45-5.90%355.43PE
VTRSViatris13.05-0.32-2.39%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.